AHR and pancreatic neoplasm: Studies in this laboratory have also focused on repositioning AhR pharmaceuticals for chemotherapeutic applications in both breast and pancreatic cancer [44,45] and have demonstrated that inhibition of tumor invasion and metastasis by OME and tranilast was AhR-dependent by tumor-specific mechanisms.